Pacira BioSciences appoints Dr. Samit Hirawat (ex-BMS CMO) to its Board of Directors

Pacira BioSciences, Inc.

Board expanded from 9 to 10 members; Hirawat appointed as Class III director, effective immediately.
Hirawat brings >25 years industry experience; most recently CMO, EVP, Head of Global Drug Development at Bristol Myers Squibb.
Hirawat appointed to Science and Technology Committee; receives standard non-employee director compensation.
Board determined Hirawat is independent under Nasdaq listing standards; no related party transactions disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.